United States Patent 7,951,797 (Drug Patent) Scope, Claim Map, and Landscape
U.S. Patent 7,951,797 has an unusually tight claim focus: it is anchored to a single, highly specific chemical entity defined by a fully specified heteroaromatic core plus stereochemical substitution, and it then expands only into (i) pharmaceutically acceptable salts, (ii) basic dosage forms (pharmaceutical compositions), and (iii) a single indication framed as insomnia via “administering a therapeutically effective amount.”
Below is the scope of claim coverage, what the claims actually protect, how a generic or follow-on product could attempt to design around, and what the landscape implications are for freedom-to-operate (FTO).
What compounds does U.S. 7,951,797 actually cover?
The patent’s core independent compound is:
5-chloro-2-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl}-1,3-benzoxazole
The claims repeatedly use the same scaffold and stereochemistry:
- Benzoxazole core: “1,3-benzoxazole”
- Chloro substitution: “5-chloro”
- Linkage at position 2: “2-{ … -1-yl}”
- Diazepane ring: “1,4-diazepan-1-yl”
- Stereocenter: “(5R)-5-methyl”
- Benzoyl group: “4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]”
- Triazole substitution pattern: “2-(2H-1,2,3-triazol-2-yl)”
Claim-by-claim chemical coverage
| Claim |
Category |
Covered subject matter |
| 1 |
Compound |
The exact compound as written (and its salts) |
| 2 |
Compound |
The exact compound (no salts explicitly added as a separate phrase, but the language matches Claim 1’s entity) |
| 7 |
Compound |
The same compound explicitly “in the form of a pharmaceutically acceptable salt” |
| 8 |
Composition |
The same compound explicitly “in the form of a pharmaceutically acceptable salt” |
| 3 |
Composition |
Composition containing the compound or its pharmaceutically acceptable salt |
| 4 |
Composition |
Composition containing the free base compound |
| 5 |
Method (insomnia) |
Administration of the compound or its salt |
| 6 |
Method (insomnia) |
Administration of the free base compound |
| 9 |
Method (insomnia) |
Administration of a closely related variant: “methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl” (see below) |
Key point: For the main entity, the compound coverage is literal and narrow because the claims are not “Markush” generalized. They specify the substitution pattern and the stereochemical designation “(5R)” in the chemical definition.
How broad are the method claims: “insomnia” only?
The method claims are:
- Claim 5: Treating insomnia by administering a therapeutically effective amount of the compound or its salt
- Claim 6: Same but limited to the free base compound
- Claim 9: Same “treating insomnia” construct, but the compound is a different benzoyl substitution variant (see next section)
Practical scope for competitors
A product would need to fall within the administered compound definition to infringe the method claims. If the product uses a different active not covered by the chemical claims, the method claims do not extend to “insomnia treatment” generally; they tie the therapeutic effect to this specific structure.
Also, the claims are framed as a human patient and insomnia, which limits coverage compared with broader “sleep disorders” or “CNS disorders” language.
What is Claim 9 actually covering that Claims 1-6 do not?
Claim 9 introduces a substitution change in the benzoyl portion:
- Claims 1-6 define benzoyl as:
“5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl”
- Claim 9 defines benzoyl as:
“methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl”
(as written in your text: “4-[methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]”)
This change removes the explicit “5-” position descriptor for the methyl on the benzoyl ring. Claim interpretation depends on the full structural context, but as drafted it is not a clean mirror of Claims 1-6.
Landscape implication
Claim 9 functions as a coverage expansion for a potentially nearby analog within the same general scaffold, at least with respect to the method-of-use context. For enforcement and FTO, Claim 9 is the line-item competitor analysis should check first for “nearby” substitution patterns in the benzoyl phenyl ring.
What is the composition claim scope (dosage forms)?
Claims 3, 4, and 8 cover pharmaceutical compositions that include:
- a “pharmaceutically acceptable carrier,” plus
- the claimed compound or salt (depending on the claim)
What is not claimed
The claims do not specify:
- tablet vs capsule vs solution vs gel
- excipient identity or percentage
- controlled-release vs immediate release
- dose range
- route of administration (oral, intranasal, etc.)
So the composition claims are carrier-plus-active constructs. That tends to capture essentially any conventional formulation route as long as the active is within the claimed chemical scope.
Where does enforceable protection likely concentrate?
Even without litigating claim construction, the structure of the claims indicates where infringement arguments typically concentrate:
- Active ingredient infringement (Claims 1, 2, 7)
These are strongest for product-based challenges because they target the compound itself (and salts).
- Formulation infringement (Claims 3, 4, 8)
These capture formulation attempts that try to focus only on dosage form differences.
- Method-of-use enforcement (Claims 5, 6, 9)
These are relevant if a party markets a product for insomnia using the claimed active.
Patent landscape: what this implies for freedom-to-operate
Without a full bibliographic record (filing date, priority, assignee, related family members), the landscape analysis must be grounded in what the claims themselves do. The claims show a single-molecule patent with narrow chemical specificity and an insomnia use carve.
1) Low chemical-genus breadth
There is no evidence in the provided claim set of a broad Markush genus covering multiple substitutions. That usually means:
- design-around has a clear path: change a structural element that is explicitly claimed (e.g., benzoxazole substitution, diazepane stereochemistry, triazole attachment, benzoyl substitution pattern), rather than relying on formulation-only differences.
2) Salt strategy matters, but only for salts
Claims 1, 3, 5 include “pharmaceutically acceptable salt thereof,” and Claim 7 and Claim 8 explicitly cover salts.
That means a competitor cannot avoid coverage simply by selling a pharmaceutically acceptable salt form if the salt corresponds to the same active molecule.
3) Use restriction is narrow to insomnia
The method claims are for treating insomnia in a human patient. If a competitor’s label or study targets a different indication, the method claims become less relevant; however, product claims (composition and compound) remain independent.
4) Formulation carve-outs are weak
Because the composition claims are carrier-plus-active, differences in excipients and delivery mechanics alone do not avoid infringement if the active ingredient is the same (or salt equivalent) and the product is a composition containing that active.
Claim map for infringement screening (actionable checklist)
Step A: Identify whether the candidate active matches the chemical definition
For the main compound (Claims 1-8, excluding the variant context in Claim 9), your screening should verify all of:
- Benzoxazole core: 1,3-benzoxazole
- Chloro: 5-chloro
- Position 2 substitution: linked to diazepane through the defined anilide-like chain described in the claim
- Diazepane ring: 1,4-diazepan-1-yl
- Stereochemistry: (5R)-5-methyl
- Benzoyl ring: includes “5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl”
- Triazole: “2H-1,2,3-triazol-2-yl” attached at the benzoyl ring in the manner described
Step B: Check whether the marketed product is the same compound or its salt
Because salts are expressly included, evaluate whether the candidate product uses:
- free base vs salt form of the same active
- “pharmaceutically acceptable salts” of the same molecule (the claims do not limit salt species)
Step C: Check method-of-use labeling/claims only if chemical scope matches
If the active matches, then:
- product use for insomnia is directly within Claims 5, 6, 9 (for the relevant active variant)
Step D: Check formulation composition
If the active matches, then:
- any pharmaceutically acceptable carrier formulation is captured by Claims 3, 4, 8
- route and dosage form do not appear to be limiting based on the provided claim text
What a design-around would likely target
Based on the claim language, a workable design-around generally requires altering at least one explicitly constrained structural element.
The most leveraged modifications, in terms of claim language exposure, are:
- Stereochemistry: changing the “(5R)” configuration to another stereoisomer (if it changes the chemical identity away from the claim)
- Core substitution: altering the “5-chloro” benzoxazole substitution
- Triazole attachment mode or identity: changing the “2H-1,2,3-triazol-2-yl” moiety or its connectivity
- Benzoyl ring substitution pattern: altering the benzoyl phenyl substitution pattern described (including the methyl’s position)
- Diazepane substitution pattern: altering “1,4-diazepan-1-yl” or “5-methyl” on that ring
By contrast, changes limited to excipients, salt selection among pharmaceutically acceptable salts of the same molecule, or labeling that changes only phrasing (without changing indication) do not address the central infringement hooks.
Key Takeaways
- Chemical scope is narrow and specific: the patent centers on one exact scaffold with explicit substitution and (5R) stereochemistry, plus pharmaceutically acceptable salts.
- Composition claims are broad in formulation mechanics: any “pharmaceutically acceptable carrier” paired with the claimed active (or its salts) is within scope.
- Method claims are limited to insomnia in a human patient and are tied to administration of the claimed compound (or the close variant in Claim 9).
- Claim 9 expands coverage toward a benzoyl-ring substitution variant in the insomnia method context; it is the primary “near-neighbor” check for competitors.
- Design-around is structural, not procedural: meaningful risk reduction likely requires changing at least one explicitly defined structural element, not just formulation or salt form.
FAQs
1) Does the patent protect all sleep disorders or only insomnia?
Only insomnia is claimed for the method-of-use claims, framed as “treating insomnia in a human patient” via administration of the defined compound (Claims 5, 6, 9).
2) If a competitor uses a different salt of the same molecule, is it still covered?
Yes. Multiple claims explicitly include “pharmaceutically acceptable salt thereof,” including compound and composition claims (Claims 1, 3, 5, 7, 8).
3) Can a competitor avoid the composition claims by changing the dosage form?
The composition claims are defined by a “pharmaceutically acceptable carrier” plus the claimed active (Claims 3, 4, 8). Without a structural change to the active, dosage form changes alone do not remove coverage based on claim language provided.
4) What is the main structural difference to check for Claim 9?
Claim 9 uses a benzoyl substituent pattern that differs from Claims 1-6 as written, reducing explicit positional specification for the methyl on the benzoyl ring. It is the key analog-risk hook.
5) Is infringement dependent on the route of administration?
The method claims require “administering” but do not specify route in the claim text provided. So route is unlikely to be a limiting discriminator compared with active-ingredient scope.
References
[1] U.S. Patent 7,951,797. Claims provided in the prompt (Claims 1-9).
